Díaz Y; Miranda E; Fred RM; Mesa R, Camafeita E; Vázquez J; Cerrudo IJ; Vilá LM; Serrano H. Abatacept alters plasma proteome in rheumatism patients [abstract]. In: RCMI Translational Science 2017 Conference; 2017 Oct 28-Nov 1; Washington, D.C. Abstract no. 05.05.003.
PURPOSE: Abatacept is a biological drug designed to reduce the symptoms and signs of rheumatoid arthritis (RA) in adult patients and juvenile idiopathic arthritis. To this date, protein changes and pathways altered by consumption of this drug have not been well characterized. In this regard, our goal was to determine the changes in plasma proteins from RA patients treated with abatacept using Quantitative Proteomics (QP). METHODS: Six adults (>21year old) with RA (per 1987 ACR classification criteria) were evaluated before and after 3 months of abatacept administration. Blood samples were collected for proteomic analysis. Plasma samples were depleted from albumin and IgG and processed by multiplexed. QP analysis was assessed after tryptic digestion and isobaric peptide labeling (iTRAQ-4-plex) using liquid chromatography coupled to mass spectrometry (LC-MS/MS-Q-ExactiveTM). RESULTS: 576 proteins (false-discovery rate< 0.05) were identified and quantified with more than 1 peptide. QP data revealed that levels of 42 proteins were significantly altered as a result of abatacept treatment. Among the observed changes, we found that Serum amyloid A-1 (P0DJ18) protein expression was down-regulated in 50% of the patients, consistent with treatment success. Inflammatory proteins were categorized in 9 groups: C-reactive protein-(1%), rheumatoid factor-(8%), serum protein A from amyloid-(7%), haptoglobin-(3%), fibrinogen-(5%), complement factors-(39%), ceruloplasmin-(3%), acid glycoprotein-1-(17%) and llpha-1 antitrypsin-antichemotrypsin-(17%). CONCLUSIONS: Our results demonstrate that abatacept induces dynamic changes in a wide spectrum of inflammatory-related proteins in plasma from RA patients. This information could lead to the identification of potential biomarkers to determine therapy effectiveness and patient’s outcome.
